Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
From: Immune Activation by Epidermal Growth Factor Receptor–Specific Monoclonal Antibody Therapy for Head and Neck Cancer Arch Otolaryngol Head Neck Surg. 2007;133(12):1277-1281. doi:10.1001/archotol.133.12.1277 Figure Legend: Figure 1. Binding of the IgG1- and IgG2-specific monoclonal antibodies (mAbs) cetuximab and panitumumab to the squamous cell carcinoma of the head and neck cell line PCI-15B. This cell line was treated with different concentrations of either of the epidermal growth factor receptor–specific mAbs (10-0.001 μg/mL) for 30 minutes at 4°C, stained with a fluorescein isothiocyanate–labeled Fc-specific mAb, and analyzed by flow cytometry. The graph shows the mean fluorescence intensity (MFI) obtained at each mAb. The error bars indicate SE. Copyright © 2007 American Medical Date of download: 5/2/2017 Association. All rights reserved. From: Immune Activation by Epidermal Growth Factor Receptor–Specific Monoclonal Antibody Therapy for Head and Neck Cancer Arch Otolaryngol Head Neck Surg. 2007;133(12):1277-1281. doi:10.1001/archotol.133.12.1277 Figure Legend: Viability of squamous cell carcinoma of the head and neck (SCCHN) cell lines after treatment with epidermal growth factor receptor– specific monoclonal antibodies (mAbs) cetuximab and panitumumab. A, The SCCHN cell line PCI-15B was treated with cetuximab or panitumumab for 18 hours and analyzed for annexin V binding as a marker for early apoptosis. The x-axis represents annexin V binding and the y-axis represents propidium iodide, a marker for necrotic cells. B, The same cell line was treated with different concentrations (0.001-10 μg/mL) of cetuximab or panitumumab 18 hours, and the supernatant was analyzed for lactate Copyright © 2007for American Medical Date of download:to5/2/2017 dehydrogenase determine cell lysis. The error bars indicate SE. Association. All rights reserved. From: Immune Activation by Epidermal Growth Factor Receptor–Specific Monoclonal Antibody Therapy for Head and Neck Cancer Arch Otolaryngol Head Neck Surg. 2007;133(12):1277-1281. doi:10.1001/archotol.133.12.1277 Figure Legend: Determination of antibody-dependent cell cytotoxicity by immune effector cells to squamous cell carcinoma of the head and neck cell lines treated with the epidermal growth factor receptor–specific monoclonal antibodies (mAbs) in 4 donors (A, donor 1; B, donor 2; C, donor 3; and D, donor 4). The PCI-15B cell line was incubated with different concentrations of cetuximab or panitumumab and with immune effector cells at an effector to target ratio of 3:1 for 18 hours. supernatants were analyzed for lactate dehydrogenase as a measure of cytotoxicity, and the results were plotted in a©graph where the x-axis represents the mAb concentration and the y-axis Copyright 2007 American Medical Date of download: 5/2/2017 represents percentage of lysis. The error bars indicate SE. Association. All rights reserved. From: Immune Activation by Epidermal Growth Factor Receptor–Specific Monoclonal Antibody Therapy for Head and Neck Cancer Arch Otolaryngol Head Neck Surg. 2007;133(12):1277-1281. doi:10.1001/archotol.133.12.1277 Figure Legend: Comparison of the dose of epidermal growth factor receptor (EGFR)-specific monoclonal antibodies required for the mediation of antibody-dependent cell cytotoxicity vs phosphorylated EGFR (pEGFR) blockade. The PCI-15B cell line was serum starved for 48 hours, treated for 2 hours with different concentrations of cetuximab or panitumumab, and then pulsed with 20 ng/mL of recombinant epidermal growth factor for 15 minutes. Cell lysates were analyzed for total EGFR and pEGFR on a Western blot. Date of download: 5/2/2017 Copyright © 2007 American Medical Association. All rights reserved.